Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

NCT05588388 is registered in ClinicalTrials.gov with Kamya Sankar as lead sponsor.

NCT NCT05588388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05588388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
Lead sponsor
Kamya Sankar
Phase
Phase 2
Overall status
Recruiting
Start date
August 11, 2024
Completion date
December 28, 2027
Enrollment
39 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer, liver metastases